References
- Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999;133: 566–74.
- Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis fac-tor-a induced cytokine production and nuclear factor-KB activation in cultured human synovial cells. J Ftheumatol 2001;28:2591–6.
- Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-KB activation in LPS-and TNF-a-stimulated THP-1 cells without interfering with IxBa degradation. Inflamm Res 2002;51: 188–94.
- Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheu-matoid synovial tissues engrafted in SCID mice. Ftheumatology (Oxf) 2003;42:1365–71.
- Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, et al. Pharmacological studies of the new antiinflammatory agent3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: antiinflammatory, analge-sic and other related properties. Arzneimittelforschung. 1992;42: 935–44.
- Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharma-cological studies on T-614, a novel anti-inflammatory agent: effect on type II collagen-induced arthritis in DBA/1J mice and sponta-neous arthritis in MFtL/1 mice. Int J Immunother 1993;9: 69–78.
- Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to delete B lymphocytes. Ftheumatology (Oxf) 2001;40:201–11.
- De Vita S, Zaja F, Sacco S, Dde Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheu-matoid arthritis; evidence for a pathogenetic role of B cells. Ar-thritis Rheum 2002;46:2029–33.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Coo-per NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: 315–24.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Gold-smith C, et al. American College of Ftheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
- Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346–53.
- Fries JF, Bloch DA, Sharp JT, McShane DJ, Spitz P, Bluhm GB, et al. Assessment of radiologic progression in rheumatoid arthritis. Arthritis Rheum 1986;29:1–9.
- Ichikawa Y, Shinozawa T. Variation of the estimation of radiologic progression in RA (in Japanese). In: Drug Evaluation Committee of the Japan Rheumatism Foundation, editors. Proceedings of the Symposium "New Developments in Drug Evaluation". Tokyo: Ikagakushuppansha; 1993. p. 23–9.
- Mikanagi K, Nishioka K, Sugawara S, Nagaya I, Yamamoto S, Shiokawa Y, et al. A prospective long term study of enteric-coated salazosulfapyridine (PJ-306) in rheumatoid arthritis (in Japanese). The Clinical Report 1991;25:1749–65.
- Nishioka N, Nobunaga M, Sakuma A. A double blind comparative study of 1 g/day, 2 g/day salazosulfapyridine and placebo in rheu-matoid arthritis (in Japanese). Ryumachi 1991;31: 327–45.
- Physician's Desk Reference. 56th ed. New Jersey: Medical Eco-nomics; 2002. p. 1753.
- Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259–66.
- van der Heijde DM, van Ftiel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasala-zine on progression of joint damage in rheumatoid arthritis. Lancet 1989;333:1036–8.
- The Australian multicentre clinical trial group. Sulfasalazine in early rheumatoid arthritis. J Ftheumatol 1992;19:1672–7.